<DOC>
	<DOC>NCT00571935</DOC>
	<brief_summary>This trial is conducted in Europe. The aim of this trial is to investigate the efficacy of insulin aspart compared to soluble human insulin on blood glucose control in children below 7 years of age with type 1 diabetes.</brief_summary>
	<brief_title>Efficacy and Safety of Insulin Aspart in MDI or CSII in Children Below 7 Years of Age With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin, Long-Acting</mesh_term>
	<criteria>Type 1 diabetes for at least 1 year HbA1c below 12.0% Treatment with regular human insulin and insulin NPH for at least 1 month Receive more than 2 injections daily Receipt of investigational product within 6 months prior to trial participation Known or suspected allergy to investigational product Receipt of of insulin aspart within 3 months prior to trial participation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>7 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>